NU7441 (KU-57788)

Catalog No.S2638

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays.

Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

NU7441 (KU-57788) Chemical Structure

NU7441 (KU-57788) Chemical Structure
Molecular Weight: 413.49

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

NU7441 (KU-57788) is available in the following compound libraries:

DNA-PK Inhibitors with Unique Features

  • Non-specific DNA-PK Inhibitor

    PI-103 DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.

  • Most Potent DNA-PK Inhibitor

    PIK-75 DNA-PK, IC50=2 nM.

  • Newest DNA-PK Inhibitor

    KU-0060648 Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

  • Classic DNA-PK Inhibitor

    NU7026 Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Product Information

  • Compare DNA-PK Inhibitors
    Compare DNA-PK Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays.
Targets DNA-PK [1]
(Cell-free assay)
mTOR [1]
(Cell-free assay)
PI3K [1]
(Cell-free assay)
ATM [1]
(Cell-free assay)
ATR [1]
(Cell-free assay)
IC50 14 nM 1.7 μM 5 μM >100 μM >100 μM
In vitro NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. [2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. [3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. [4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. [5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NCI-H1770MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfBboxKSzVyPUCuNFIyPDNizszNM1r4bHNCVkeHUh?=
A172MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTBwMUWzNVYh|ryPMVrTRW5ITVJ?
NCI-H526NWLOUmszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTBwMki0NFch|ryPM3jnOnNCVkeHUh?=
HDLM-2MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjrU5Q{UUN3ME2wMlMzOzR3IN88US=>NUnNdZN6W0GQR1XS
HuO-3N1NIGxO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF60eIlKSzVyPUCuOFY3OzZizszNNIrVOmRUSU6JRWK=
NCI-SNU-1NVe2OFFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVr4T5FWUUN3ME2wMlYxQTl2IN88US=>M3HXfnNCVkeHUh?=
SK-N-ASM{XpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW[yXXp4UUN3ME2wMlYzOjF4IN88US=>NVLqZmM2W0GQR1XS
LoVoNHnu[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIL5NY1KSzVyPUCuPFY4PDlizszNNEDiXJhUSU6JRWK=
LAMA-84M3jOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTBwOUi4N|Mh|ryPMVTTRW5ITVJ?
CTB-1M1T1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2WwV2lEPTB;MT6xNVU1PiEQvF2=M3vlPHNCVkeHUh?=
KP-N-YSNVXvWpJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\odGtKSzVyPUGuNVQzOzFizszNMWHTRW5ITVJ?
HHNHnXR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYm3WphuUUN3ME2xMlE5ODl|IN88US=>MoHkV2FPT0WU
CHL-1MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojHTWM2OD1zLkKxN|Y5KM7:TR?=MnizV2FPT0WU
NB7NVywcJpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXtTWM2OD1zLkK0O|Q2KM7:TR?=M4W1[XNCVkeHUh?=
HL-60MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjpdIJKSzVyPUGuN|gyQSEQvF2=NVjz[2J2W0GQR1XS
639-VMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTFwNESxNlgh|ryPNYfocmdIW0GQR1XS
NCI-H1793NV\6RYxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLTTWM2OD1zLkS1PFQh|ryPMVPTRW5ITVJ?
NEC8M1PGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXDXHBKSzVyPUGuOVU{PSEQvF2=NVPocYJTW0GQR1XS
PA-1NYHnWmp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7kTWM2OD1zLkW4Nlk1KM7:TR?=NITRNZZUSU6JRWK=
D-423MGMlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmC2TWM2OD1zLk[5N|YyKM7:TR?=NETieVlUSU6JRWK=
NCI-H292MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXUVYRKSzVyPUGuO|QxOTNizszNMWjTRW5ITVJ?
SK-MEL-1NHLNT4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTFwN{m0O|kh|ryPNVHwZlJSW0GQR1XS
LB2241-RCCNFHLNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTJwMUSxOFYh|ryPMV\TRW5ITVJ?
SK-MEL-3MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\FVlJKSzVyPUKuNVY1QSEQvF2=M1nEWXNCVkeHUh?=
MHH-PREB-1NULob2JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTJwMU[2NFkh|ryPMmnnV2FPT0WU
BFTC-905MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTJwMU[2PFch|ryPNH7MVHlUSU6JRWK=
Ramos-2G6-4C10M4nYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofUTWM2OD1{LkG5PVA6KM7:TR?=M3Wx[HNCVkeHUh?=
G-361M2\PXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTJwMkG2PEDPxE1?MkC2V2FPT0WU
MOLT-4M33ZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrtd2xJUUN3ME2yMlIyQDh6IN88US=>MYTTRW5ITVJ?
DELNIHa[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPNcYpuUUN3ME2yMlM2PTZ2IN88US=>MkO2V2FPT0WU
MV-4-11NIHFSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHNNmRKSzVyPUKuN|c{QSEQvF2=NF\hbJFUSU6JRWK=
SK-NEP-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHOzSZZKSzVyPUKuN|g4QDNizszNMYPTRW5ITVJ?
RS4-11M{\RdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nWNmlEPTB;Mj61OlAzOyEQvF2=MoHiV2FPT0WU
HuH-7NIP6eXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjQVoVHUUN3ME2yMlU3PzB{IN88US=>MVzTRW5ITVJ?
A101DNI\QflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1iyOGlEPTB;Mj62NVM{QCEQvF2=NXT1eVN{W0GQR1XS
KG-1MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTJwNke5NlQh|ryPMYLTRW5ITVJ?
KALS-1MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTJwNkm2N|Mh|ryPM4fGWHNCVkeHUh?=
VMRC-RCZMl3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PtRWlEPTB;Mj63O|MzQCEQvF2=MUfTRW5ITVJ?
SK-UT-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1Xr[2lEPTB;Mz6xOVMyKM7:TR?=Mn\UV2FPT0WU
SW962Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3NRnZKSzVyPUOuNlA{PTJizszNM2TMfHNCVkeHUh?=
DBTRG-05MGMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17MdGlEPTB;Mz6yPFA5PSEQvF2=NHnxfG5USU6JRWK=
PANC-08-13MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHSzOYpKSzVyPUOuOFEzPzhizszNM3PuSXNCVkeHUh?=
QIMR-WILNUjCT|A2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlr1TWM2OD1|LkSxN|QyKM7:TR?=M4DvXXNCVkeHUh?=
SK-MEL-30MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXtTWM2OD1|LkSyOVk5KM7:TR?=NFrOXHZUSU6JRWK=
697M16x[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XTUWlEPTB;Mz60OFk6OyEQvF2=MoToV2FPT0WU
NYMlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TkSWlEPTB;Mz60OVAzOiEQvF2=MkLTV2FPT0WU
ES7NUHiWm1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPa[VFHUUN3ME2zMlQ3PzJ7IN88US=>MXPTRW5ITVJ?
JVM-3NWLXfmdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoO4TWM2OD1|LkS4NFc4KM7:TR?=MXfTRW5ITVJ?
U031M2D0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTNwNUmzOlgh|ryPMYLTRW5ITVJ?
BHT-101M4TGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjYTWM2OD1|LkW5PVg2KM7:TR?=NYjkS2Y{W0GQR1XS
8305CNITq[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLMTWM2OD1|Lk[xO|M3KM7:TR?=M3uwOHNCVkeHUh?=
MG-63MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTpTWM2OD1|Lk[yOlc3KM7:TR?=M2jSc3NCVkeHUh?=
NOS-1M17QNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLQTWM2OD1|Lk[1N|EzKM7:TR?=MoG3V2FPT0WU
YH-13NEDp[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfXW2tKSzVyPUOuPFcyQDlizszNMXzTRW5ITVJ?
LXF-289MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVKxd3RnUUN3ME2zMlkyODRzIN88US=>NVSyS2FEW0GQR1XS
GOTONUTKbWc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjy[nBKSzVyPUOuPVE1QSEQvF2=MWfTRW5ITVJ?
EKVXMnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTRwMkK1NlQh|ryPNHvVN3JUSU6JRWK=
CAL-51NV7hNoJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPqOFhKSzVyPUSuNlQ5PTRizszNNFfHOphUSU6JRWK=
AN3-CAMnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH[2SmRKSzVyPUSuNlU5OTNizszNMUHTRW5ITVJ?
IA-LMNX6xbYdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTRwMke5N|Uh|ryPM{HHbnNCVkeHUh?=
KU-19-19MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTRwM{K5NlEh|ryPM37od3NCVkeHUh?=
A704MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjlXIU5UUN3ME20MlQxQDh6IN88US=>NFTG[2NUSU6JRWK=
RH-18NXTyPY5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTRwNES5OVMh|ryPNIW5WlNUSU6JRWK=
IST-MEL1MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjyTWM2OD12LkW4NlY{KM7:TR?=MnjCV2FPT0WU
LU-134-AM1\v[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\GWoRtUUN3ME20MlU6Pjh3IN88US=>NWT2UY1VW0GQR1XS
SF126Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vWb2lEPTB;ND62NFcyPSEQvF2=MUPTRW5ITVJ?
EFO-27NYLZO5RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXlTWM2OD12Lk[2OVI2KM7:TR?=NVHRUnAzW0GQR1XS
SN12CM4fxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPmNZZTUUN3ME20MlcyQDl6IN88US=>Mlq5V2FPT0WU
L-363MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGixSIpKSzVyPUSuO|cyOTZizszNMkfIV2FPT0WU
MEL-HOM{mxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTRwN{e5PFkh|ryPNEmzb4FUSU6JRWK=
TYK-nuNIXTSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vQcWlEPTB;ND64NFEzQCEQvF2=NH3RbGZUSU6JRWK=
MDA-MB-415MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\0cYpKSzVyPUWuNFA{OTRizszNNGO5[m1USU6JRWK=
HCC70NV3nOJRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7hTWM2OD13LkCzPVM6KM7:TR?=MVPTRW5ITVJ?
IGROV-1Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;CRYV6UUN3ME21MlI2Ojl{IN88US=>NF\FbnBUSU6JRWK=
NCI-H1355M2nYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\FNXA3UUN3ME21MlI6PiEQvF2=NIPKO2pUSU6JRWK=
23132-87MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDmTWM2OD13LkOyNFI1KM7:TR?=MXvTRW5ITVJ?
NB69MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTVwM{K0NkDPxE1?MmL6V2FPT0WU
HSC-2NEDXeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHhZmJKSzVyPUWuOFE4PzNizszNNUH3fVg4W0GQR1XS
KYSE-410NWjSc28yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHCenRYUUN3ME21MlQ4PjN4IN88US=>M3G1dnNCVkeHUh?=
GCIYNF;SOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTVwNUGzO|gh|ryPNEfOTFhUSU6JRWK=
A427MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\JTWM2OD13LkWzOlYyKM7:TR?=NGDnfnJUSU6JRWK=
ChaGo-K-1M{\LZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV62RYQ2UUN3ME21MlU3PTl7IN88US=>M375fnNCVkeHUh?=
PFSK-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1uyS2lEPTB;NT62NlE6PCEQvF2=MnOwV2FPT0WU
MLMAMlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPoNopKSzVyPUWuPFM3ODZizszNM3jYcnNCVkeHUh?=
RVH-421NWLiOZByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\YOWZ3UUN3ME22MlA4OzN6IN88US=>MXLTRW5ITVJ?
LB1047-RCCNH;WT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjidGlKSzVyPU[uNVc2OjJizszNM{C1V3NCVkeHUh?=
MHH-NB-11MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTZwM{K3NlEh|ryPMkn3V2FPT0WU
J-RT3-T3-5MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWmwNGlFUUN3ME22MlY{OjlzIN88US=>NYn3WnE3W0GQR1XS
UM-UC-3NEHEVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTZwNkSzN|Qh|ryPNVPnS3VmW0GQR1XS
IST-SL1MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIi1[mFKSzVyPU[uOlk{PjlizszNNIjXd3RUSU6JRWK=
NB14NI\uOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTZwN{m3OlEh|ryPNGX0dWhUSU6JRWK=
NBsusSRMmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXoXmtKSzVyPU[uPFI2ODJizszNNVzCTIdxW0GQR1XS
D-263MGNXnIS5ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYD1WIsxUUN3ME22MlkyODZ6IN88US=>NHzZTItUSU6JRWK=
NCI-H2347NFrGNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTZwOUOyNVMh|ryPNEPtbGdUSU6JRWK=
ES8NGXneWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTZwOUe1PFgh|ryPNFn0O|BUSU6JRWK=
786-0NHnsPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTdwMEm3PFYh|ryPNYjlOZdTW0GQR1XS
EPLC-272HNHnQNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjle5RWUUN3ME23MlE3OjR4IN88US=>MnntV2FPT0WU
CAPAN-1Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;JTWM2OD15LkK0N|U6KM7:TR?=M1jSbXNCVkeHUh?=
NCI-H82M1HEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTHeWFKSzVyPUeuNlY3PTlizszNMoTlV2FPT0WU
G-402MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LwVWlEPTB;Nz6zNFA2OSEQvF2=MWfTRW5ITVJ?
SW982Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M37hS2lEPTB;Nz6zNFIxOyEQvF2=NEL5bm5USU6JRWK=
OVCAR-4NHntbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DO[GlEPTB;Nz6zNVMzQCEQvF2=M3HQVXNCVkeHUh?=
KARPAS-299MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTdwM{K2NlIh|ryPM2SxT3NCVkeHUh?=
MIA-PaCa-2MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\QTWM2OD15LkO2PFI{KM7:TR?=NXzWZY41W0GQR1XS
AU565M3XhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfRTWhKSzVyPUeuOVk5OzNizszNNEnLTIJUSU6JRWK=
GAMGMkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rEWGlEPTB;Nz62OFE{OSEQvF2=MUXTRW5ITVJ?
HuO9NHP4V3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEG2SI5KSzVyPUeuO|E4PDNizszNNILQTZFUSU6JRWK=
ACNNWfWR45iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;CSpNHUUN3ME23Mlc1OzNizszNMYPTRW5ITVJ?
RO82-W-1M17jd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTdwN{S1N|Mh|ryPMWLTRW5ITVJ?
NKM-1NHzvS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LVPWlEPTB;Nz63OFk2PSEQvF2=NH7FOWZUSU6JRWK=
CAL-12TNGn2WY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInZc|ZKSzVyPUeuPVQ{PTJizszNMXfTRW5ITVJ?
FADUM4f5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHi3[45KSzVyPUiuNFM3PTRizszNNVrxN3BKW0GQR1XS
NCI-H28MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrFTWM2OD16LkG2PVYzKM7:TR?=NX7lSW9CW0GQR1XS
LCLC-97TM1M3P1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDkZY1KSzVyPUiuNlEyOjJizszNNHz4[I9USU6JRWK=
CHP-134NFTUfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkP6TWM2OD16LkK0NVg2KM7:TR?=NYn2SVdFW0GQR1XS
HT-1080NWftS3lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXtR444UUN3ME24MlI2ODl|IN88US=>Mn3EV2FPT0WU
PC-3NVP3To1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGi4bYJKSzVyPUiuNlc{QTJizszNMVzTRW5ITVJ?
SNU-449MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXQNINKSzVyPUiuNlc6OyEQvF2=MVvTRW5ITVJ?
VA-ES-BJNVPZcoozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoGzTWM2OD16LkO0Olg3KM7:TR?=MVrTRW5ITVJ?
HTNVPESnhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HTRmlEPTB;OD6zOlQ6KM7:TR?=M1PXeHNCVkeHUh?=
HOSMlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoP6TWM2OD16LkO3OVg6KM7:TR?=NHXyTFNUSU6JRWK=
KNS-62MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUCxWZRkUUN3ME24MlM4PzZ{IN88US=>MVrTRW5ITVJ?
OAW-42MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnMTWM2OD16Lkm1PVY1KM7:TR?=M3XFcnNCVkeHUh?=
A549NX\5fHZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXWS2JiUUN3ME25MlA6PjF{IN88US=>MV7TRW5ITVJ?
CAKI-1NV:1emszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;Veo5KSzVyPUmuNVY3OSEQvF2=Mn;jV2FPT0WU
HCC1937MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;sTWM2OD17Lk[5PFY2KM7:TR?=MmfEV2FPT0WU
GI-ME-NMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULkWoN7UUN3ME25MlcxOTN5IN88US=>MkO0V2FPT0WU
DU-4475MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33OOmlEPTB;OT65Olk{QSEQvF2=MUnTRW5ITVJ?
EM-2NUfWXXAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUG2TlVkUUN3ME2xNE4zPDJ4IN88US=>M1L6SXNCVkeHUh?=
NCI-H1755NYHD[Y84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHxTWM2OD1zMD6yOFI5KM7:TR?=NV3zNG85W0GQR1XS
NCI-H1437NXHzXGFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\pdpE1UUN3ME2xNE42PzJ3IN88US=>NIezU|RUSU6JRWK=
VM-CUB-1MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfGbY1KSzVyPUGwMlYyPjRizszNMUHTRW5ITVJ?
A2058NW\pSJozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLETWM2OD1zMD62OFA1KM7:TR?=NH;VOWlUSU6JRWK=
BPH-1NGi0WVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrDTWM2OD1zMD63NVQ2KM7:TR?=MXjTRW5ITVJ?
NB5NIHOVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTFyLke1OVkh|ryPNEjkdopUSU6JRWK=
G-401MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXBV3NKSzVyPUGwMlc3OjZizszNNH\aOZlUSU6JRWK=
CAL-72MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTFyLkiwPVQh|ryPMVLTRW5ITVJ?
SK-MEL-28NWnuZ|BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTFyLkiyNFIh|ryPNHvTcHBUSU6JRWK=
C32MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vRS2lEPTB;MUCuPFM1PyEQvF2=MYDTRW5ITVJ?
NCI-H1155M2XBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fBZWlEPTB;MUCuPFM4PiEQvF2=NWLhc4RMW0GQR1XS
BB49-HNCMkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fPcmlEPTB;MUCuPFU5PiEQvF2=MUTTRW5ITVJ?
GMS-10MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;mcY1KSzVyPUGwMlg6PzFizszNNUO0NVJpW0GQR1XS
K5NIDWUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\xb5JuUUN3ME2xNE46ODdzIN88US=>NGLhcGxUSU6JRWK=
OS-RC-2MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnz3TWM2OD1zMT6wOVU6KM7:TR?=MVPTRW5ITVJ?
HTC-C3MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXyzVVFTUUN3ME2xNU4xPzF2IN88US=>MY\TRW5ITVJ?
LB996-RCCM3zTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGe0W3FKSzVyPUGxMlA4OjNizszNMnThV2FPT0WU
NCI-H1563Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTFzLkGwNVEh|ryPNVL3S3luW0GQR1XS
CAL-54NI\LPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVGxeXg3UUN3ME2xNU41QDFzIN88US=>M4rkfHNCVkeHUh?=
WM-115MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PKbWlEPTB;MUGuOlgzPCEQvF2=NI\DfZRUSU6JRWK=
COLO-684M{focmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\sUGlEPTB;MUGuO|I3PyEQvF2=NXvuXIhTW0GQR1XS
HOP-62MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW[yO2ZyUUN3ME2xNU44PTB6IN88US=>NHvON4ZUSU6JRWK=
NCI-H650NXXNUIVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTFzLki5OlEh|ryPNUn2bVY1W0GQR1XS
TE-11MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLXcIp6UUN3ME2xNU46OzF3IN88US=>MmrzV2FPT0WU
COLO-679MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTFzLkm0OkDPxE1?NYPhd3FSW0GQR1XS
FTC-133MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTF{LkCwO|Yh|ryPMUDTRW5ITVJ?
D-283MEDNGrnfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDibXRKSzVyPUGyMlA2PjlizszNMU\TRW5ITVJ?
SK-PN-DWNF7IWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHnSWdKSzVyPUGyMlE6ODJizszNM3vHTHNCVkeHUh?=
BALL-1MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XadmlEPTB;MUKuNlY3OiEQvF2=MX7TRW5ITVJ?
GT3TKBNFLLcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nz[2lEPTB;MUKuN|A4PCEQvF2=MUTTRW5ITVJ?
HOP-92NGGxOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXDV4c4UUN3ME2xNk42OjN|IN88US=>MYrTRW5ITVJ?
M14NXX5VlMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHrd3BUUUN3ME2xN{4xOzN3IN88US=>MojPV2FPT0WU
SKG-IIIaMmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mly1TWM2OD1zMz6wOVU1KM7:TR?=MVnTRW5ITVJ?
BeckerMl;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zTRmlEPTB;MUOuNFU5KM7:TR?=MV\TRW5ITVJ?
ES5NVvLWIF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTF|LkGzOVYh|ryPM3zHWHNCVkeHUh?=
NCI-H2030MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fQdWlEPTB;MUOuNlA3OiEQvF2=NYXMeFRLW0GQR1XS
SNU-423NYXOe|JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3[xcWlEPTB;MUOuN|gyKM7:TR?=NX\LWGZGW0GQR1XS
CP50-MEL-BM1TxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTF|Lk[yN|Ih|ryPNVPENld2W0GQR1XS
NCI-H1092M{m2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfPTWM2OD1zMz63OFc2KM7:TR?=MmLxV2FPT0WU
8-MG-BANGexcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLHTWM2OD1zMz63OVE{KM7:TR?=MkL6V2FPT0WU
CAL-27NVHRUnJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTpTWM2OD1zND6wO|I4KM7:TR?=Ml\IV2FPT0WU
AGSNGr6[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\YSms2UUN3ME2xOE4yOzF7IN88US=>MVXTRW5ITVJ?
MZ2-MELMnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYf1UodIUUN3ME2xOE4yPDh6IN88US=>M2j2fnNCVkeHUh?=
BFTC-909MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnX0TWM2OD1zND61NFU2KM7:TR?=NWT5RlB7W0GQR1XS
D-566MGMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DTfmlEPTB;MUSuO|cxPiEQvF2=MknsV2FPT0WU
MZ7-melMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\ETWM2OD1zNT6xNFY4KM7:TR?=Mmq2V2FPT0WU
TE-5M2jKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3aTWM2OD1zNT6yN|M{KM7:TR?=Mn7lV2FPT0WU
647-VNFK0fY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3Xmd2lEPTB;MUWuNlcxPSEQvF2=MWjTRW5ITVJ?
DMS-114M121SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTF3LkOyPVEh|ryPNF\5W4lUSU6JRWK=
ME-180NHTCe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTF3LkS3PFMh|ryPM2D3c3NCVkeHUh?=
MS-1M1[xVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTF3LkW2NlMh|ryPMXXTRW5ITVJ?
NUGC-3M4\jbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnpTWM2OD1zNT62NlQ2KM7:TR?=M{DQUnNCVkeHUh?=
GB-1NW\yb3c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrRTWM2OD1zNT62OFM4KM7:TR?=NUf1cJVKW0GQR1XS
LOXIMVIMnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV:yc4NMUUN3ME2xOU45QTF7IN88US=>NUf4bJhjW0GQR1XS
NCI-H1304MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzLTWM2OD1zNT64PVI5KM7:TR?=M33qO3NCVkeHUh?=
KURAMOCHINGi5RWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTF3Lkm3NUDPxE1?NEC3UXdUSU6JRWK=
SW1783NV7CUIxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGW1ZlBKSzVyPUG2MlA6QTNizszNM{nOXXNCVkeHUh?=
EGI-1M1T3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTF4LkWzOlUh|ryPM4DISnNCVkeHUh?=
KGNMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;6b2lEPTB;MU[uOVU5PiEQvF2=MWDTRW5ITVJ?
PANC-03-27NUT5UlhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrxNoJKSzVyPUG2Mlc3PjJizszNM1ntSXNCVkeHUh?=
RH-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTF4LkiyOUDPxE1?NWj2OWpuW0GQR1XS
HT-1376MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTF4Lki0OFYh|ryPNFy5WFVUSU6JRWK=
ZR-75-30MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;MdXVKSzVyPUG2Mlk{PjFizszNMkizV2FPT0WU
TI-73Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTF4Lkm0NFgh|ryPMW\TRW5ITVJ?
TK10MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlS5TWM2OD1zNz6wNFc6KM7:TR?=MVrTRW5ITVJ?
SW684NXTSZXZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2WwcGlEPTB;MUeuNFE2PCEQvF2=NGP4eGJUSU6JRWK=
RPMI-8866MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjCTWM2OD1zNz6wOlk6KM7:TR?=NVLlb4ppW0GQR1XS
LNCaP-Clone-FGCNHHO[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXlSY1KSzVyPUG3MlUzODFizszNM3jDUXNCVkeHUh?=
NCI-H2291NFjjU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPBeHZKSzVyPUG4MlQ{PDVizszNM1PIOXNCVkeHUh?=
T47DM3vUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnJcmx7UUN3ME2xPE41QDhizszNM13uOnNCVkeHUh?=
A204NVXYOZc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TaVWlEPTB;MUiuOVQ2OiEQvF2=NGPBfJlUSU6JRWK=
HT-144M1LlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fXRWlEPTB;MUiuO|QzPyEQvF2=NVy4UnY{W0GQR1XS
MDA-MB-361NUnoR2l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnpeYtKSzVyPUG5MlA4OTRizszNM2fKN3NCVkeHUh?=
HCC1806NH;yZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HTcmlEPTB;MUmuNVU6OSEQvF2=NGrlSJJUSU6JRWK=
NCI-H596M3TrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TId2lEPTB;MUmuOlM6OSEQvF2=NVT3RoVqW0GQR1XS
K-562NYfDTI05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrhTWM2OD1zOT64PVI3KM7:TR?=MVTTRW5ITVJ?
D-336MGNWnifYh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTkTWM2OD1zOT65N|IzKM7:TR?=M2\lU3NCVkeHUh?=
SK-MEL-2NILaPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTJyLkG1OVkh|ryPNGTTSGtUSU6JRWK=
HEC-1MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzacGNGUUN3ME2yNE41QTd6IN88US=>NX62Z5RsW0GQR1XS
EW-13MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\LcI1KSzVyPUKwMlU1PDNizszNMlPRV2FPT0WU
Hs-578-TMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;oXFZKSzVyPUKwMlU2QDNizszNNV7H[WdbW0GQR1XS
SJSA-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\JfGlEPTB;MkCuOVY5QCEQvF2=MVvTRW5ITVJ?
RCC10RGBMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml74TWM2OD1{MD62O|E6KM7:TR?=NV\TR3dvW0GQR1XS
LAN-6MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfrdoZ1UUN3ME2yNU4xOzl4IN88US=>MoPjV2FPT0WU
NCI-H1048NVXsRpJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17XT2lEPTB;MkGuNlI2QCEQvF2=NVrMcXFxW0GQR1XS
CW-2NW\3XZhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTXfXJbUUN3ME2yNU4zPzB3IN88US=>MYDTRW5ITVJ?
HCC2157NF\BWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGr1dVZKSzVyPUKxMlM3KM7:TR?=NHzzTIdUSU6JRWK=
EW-22MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTJzLkO3OkDPxE1?MUjTRW5ITVJ?
A253M2m5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfZNJpKSzVyPUKxMlQ1QDFizszNNI[4XIlUSU6JRWK=
BE-13MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXST3Z7UUN3ME2yNU43OTF|IN88US=>NIjnRpRUSU6JRWK=
KINGS-1NYXIXGZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTJzLk[zNVYh|ryPMlGzV2FPT0WU
ETK-1NUmy[WhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTJzLkixOVIh|ryPMkH6V2FPT0WU
NCI-H2452M3;Db2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTJzLki2OFch|ryPMn\vV2FPT0WU
HPAF-IIM1vCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTJzLki5NlMh|ryPMX\TRW5ITVJ?
D-542MGMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXpTWM2OD1{MT65NFY6KM7:TR?=NX3jbmZkW0GQR1XS
NCI-H630NWf3XVc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{SwcWlEPTB;MkKuNFI6PiEQvF2=NVPSdItbW0GQR1XS
TGBC11TKBMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\jTWM2OD1{Mj6wOFkh|ryPM1;4T3NCVkeHUh?=
BCPAPMlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrhbnB4UUN3ME2yNk43OTFizszNM{GxbHNCVkeHUh?=
HLEM{\ZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M12zUmlEPTB;MkKuOlk4KM7:TR?=MXjTRW5ITVJ?
NCI-H727NELtN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTJ{LkezOUDPxE1?M2X2O3NCVkeHUh?=
RDNFXHe4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXOZpZXUUN3ME2yNk44PTF6IN88US=>MlzuV2FPT0WU
NCI-H522M4P0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{OwWWlEPTB;MkKuPFQ{OSEQvF2=MYLTRW5ITVJ?
CGTH-W-1M1PacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPxTWM2OD1{Mz6wOlQyKM7:TR?=NIXqS3pUSU6JRWK=
SK-LU-1NH63So5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULhfYRJUUN3ME2yN{41Pjh|IN88US=>NInYd2FUSU6JRWK=
BB65-RCCMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnLbWhtUUN3ME2yN{44QDZ|IN88US=>MV3TRW5ITVJ?
HSC-3MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULhZ4F2UUN3ME2yN{45PTJ5IN88US=>MYjTRW5ITVJ?
SK-MES-1NV3T[ZdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHa[HpKSzVyPUK0MlAyPjFizszNNGnwW3ZUSU6JRWK=
DBNIOxeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTJ2LkGwNlgh|ryPMlniV2FPT0WU
HO-1-N-1MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1i3RmlEPTB;MkSuN|A6OyEQvF2=MX3TRW5ITVJ?
MKN1M{fqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXzTWM2OD1{ND62PEDPxE1?NV64e|ZVW0GQR1XS
MN-60MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XPfGlEPTB;MkSuPFUyQSEQvF2=NFO3OWhUSU6JRWK=
8505CMlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjWeZVKSzVyPUK1MlE5PDVizszNM1\ocnNCVkeHUh?=
COLO-320-HSRMljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEThOFdKSzVyPUK1MlIzODhizszNNWOwOHFkW0GQR1XS
BB30-HNCNYrrSppRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rke2lEPTB;MkWuNlQ5OyEQvF2=M1W5bnNCVkeHUh?=
KM12MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTJ3LkW4NFch|ryPMYrTRW5ITVJ?
NB13NHLmS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\QemlEPTB;MkWuOVg6QCEQvF2=M361dXNCVkeHUh?=
HCC2998MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTJ4LkCyPFMh|ryPNYnzeJRoW0GQR1XS
U-118-MGNIP1OoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTJ4LkC4NFgh|ryPMl\HV2FPT0WU
NB10MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrMXlVqUUN3ME2yOk4zOzRizszNNVvFeXFNW0GQR1XS
SK-LMS-1MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTJ5LkC3NFQh|ryPNWmyTHg4W0GQR1XS
SW1573NVLFcpdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfifINKSzVyPUK3MlEyKM7:TR?=NF;rfVlUSU6JRWK=
LB373-MEL-DMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M124W2lEPTB;MkeuNVI6PCEQvF2=M3nxWXNCVkeHUh?=
DK-MGM1;RXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGS0ZmFKSzVyPUK3MlE5OTdizszNM4DkTHNCVkeHUh?=
RMG-IMn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jQW2lEPTB;MkeuNlAzQSEQvF2=NH7RUGNUSU6JRWK=
SW1088NEi2fVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEj5eJlKSzVyPUK3MlUxPDJizszNMlLoV2FPT0WU
SK-OV-3MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTPTWM2OD1{Nz63OVk{KM7:TR?=MYLTRW5ITVJ?
KP-N-YNMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTJ5LkiwOFMh|ryPMY\TRW5ITVJ?
RPMI-7951MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmO4TWM2OD1{OD6yOFU3KM7:TR?=NX;mbFM3W0GQR1XS
CaR-1NFmwdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moj0TWM2OD1{OD61OVgzKM7:TR?=MXLTRW5ITVJ?
MKN7NH\mdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlGyTWM2OD1{OD61PVY1KM7:TR?=NYnTO5I3W0GQR1XS
CHP-212NXzlXpJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTJ6Lke0NFEh|ryPM2\3UXNCVkeHUh?=
KYSE-450MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXzTWM2OD1{OD64NFkyKM7:TR?=MoPnV2FPT0WU
RXF393M2XnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTJ7LkK5NFYh|ryPNYfQVZRHW0GQR1XS
P30-OHKMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmKxTWM2OD1{OT6zNFQ5KM7:TR?=M2XDb3NCVkeHUh?=
Ca9-22MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLJNo9KSzVyPUK5MlQzQTlizszNNEe1R|NUSU6JRWK=
RT-112M3i0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfE[5VKSzVyPUK5MlQ3OTFizszNNXHZPYo{W0GQR1XS
ES1NGLDcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTJ7Lki1OFQh|ryPNEDXcG1USU6JRWK=
HCE-4NX3Ue5UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHBeY9KSzVyPUK5Mlg4QDZizszNM2j5VXNCVkeHUh?=
AM-38NH7S[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPlbY1jUUN3ME2zNE4xPjB4IN88US=>NFn3W3ZUSU6JRWK=
AsPC-1Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHWTYlKSzVyPUOwMlgxPTNizszNMYHTRW5ITVJ?
TE-9NFf1fYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHHTWM2OD1|MD64O|M4KM7:TR?=NUj6[GllW0GQR1XS
HuP-T4MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEn0flJKSzVyPUOwMlk3OzhizszNNUfycI15W0GQR1XS
LB2518-MELNEn2V2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTLTWM2OD1|MT6wO|Q1KM7:TR?=NXv2T29qW0GQR1XS
NCI-H1703Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7WdWpKSzVyPUOxMlA6ODVizszNMWTTRW5ITVJ?
NCI-H2228NWHQNYdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG[yfGtKSzVyPUOxMlQ3PTFizszNNXPwfZA3W0GQR1XS
SCC-4MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkHVTWM2OD1|MT65NVgyKM7:TR?=MlLyV2FPT0WU
KNS-81-FDNULz[HRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2i0emlEPTB;M{KuNFEzQCEQvF2=MX7TRW5ITVJ?
NTERA-S-cl-D1NWjoXXd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnoXJZPUUN3ME2zNk4xPzN7IN88US=>NXL2NYZ4W0GQR1XS
DaoyNEDmXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLwTWM2OD1|Mj6wPFM5KM7:TR?=NXjLT4FSW0GQR1XS
ES4NITv[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\DendKSzVyPUOyMlM6OjJizszNMX\TRW5ITVJ?
MHH-ES-1M3LEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;u[mlEPTB;M{KuOFg4OiEQvF2=NXzROIdvW0GQR1XS
C-33-AM3jGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEO3XmVKSzVyPUOyMlc4OjhizszNNIrNNIVUSU6JRWK=
BHYM33DUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TaeWlEPTB;M{KuPVQ6PSEQvF2=MXXTRW5ITVJ?
Detroit562M3n3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPJdVVKSzVyPUOzMlY3PTdizszNNF;TPIdUSU6JRWK=
EW-1M2PJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTN|LkmzNlIh|ryPMnPLV2FPT0WU
NCI-H1395M{fVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnH2TWM2OD1|ND6wO|k6KM7:TR?=NHHnWlRUSU6JRWK=
KM-H2M1SzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTN4LkS3OFMh|ryPMUjTRW5ITVJ?
NCI-H520NWi0[4xqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4K3Z2lEPTB;M{[uO|U1OSEQvF2=M3rpZnNCVkeHUh?=
D-392MGM4\ZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\STWM2OD1|Nz6zN|Q1KM7:TR?=MWDTRW5ITVJ?
NOMO-1MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjPVG9KSzVyPUO3MlgxQDlizszNM{\MbnNCVkeHUh?=
TE-6NEDFRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4W1emlEPTB;M{iuNVI1KM7:TR?=M4njcHNCVkeHUh?=
HT-3MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;IdIl6UUN3ME2zPE41PDN4IN88US=>MWTTRW5ITVJ?
RPMI-8226MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTN6Lkm1NVkh|ryPNITNNIRUSU6JRWK=
U251NF2wS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3L0V2lEPTB;M{muNFEzPCEQvF2=NXjKUmdzW0GQR1XS
GCTNHP0ZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHZ[45KSzVyPUO5MlE5PTJizszNMXjTRW5ITVJ?
A431NYfIZYx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEGwPXJKSzVyPUO5MlE5QTRizszNMlzuV2FPT0WU
TE-12Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEeyWWtKSzVyPUO5MlI1PDhizszNMl7PV2FPT0WU
HMV-IIMk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;4[FM4UUN3ME2zPU42ODR5IN88US=>MXTTRW5ITVJ?
IST-MES1M{fiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17zNGlEPTB;NECuNVUxOiEQvF2=MlPnV2FPT0WU
SW13NF3DfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXrS|NKSzVyPUSwMlUyQSEQvF2=NYXUOZRoW0GQR1XS
SF295MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTRyLkiwOlYh|ryPNWPjOpdSW0GQR1XS
MDA-MB-157M1ThbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jYV2lEPTB;NECuPVQ3OiEQvF2=MXnTRW5ITVJ?
TE-1M2j6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTRzLki3NVQh|ryPMkHaV2FPT0WU
HuCCT1NH\hOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7y[2pnUUN3ME20Nk42Ojh7IN88US=>NVXrSIJmW0GQR1XS
KYSE-510MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTR|LkG3OVQh|ryPNEjE[oFUSU6JRWK=
NCI-H358NYnSWVVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLtTWM2OD12ND6wN|A1KM7:TR?=NGX5V|VUSU6JRWK=
SW900M3f1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzWNIV{UUN3ME20OE4xPzV6IN88US=>MlXWV2FPT0WU
CAS-1MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILWe4ZKSzVyPUS0MlA6QTFizszNM13Mc3NCVkeHUh?=
TE-8NITFOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXUS5RKSzVyPUS0MlU3PThizszNNXO1cYNxW0GQR1XS
P12-ICHIKAWAM4XMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjPfmVKSzVyPUS0MlYyOTJizszNNVTPWmJUW0GQR1XS
YKG-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXNN3dKSzVyPUS0Mlc5OSEQvF2=NX\lRoF{W0GQR1XS
SNU-C2BNU\FfJM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHCb3JvUUN3ME20OE44QTB|IN88US=>MWXTRW5ITVJ?
LCLC-103HMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTR2Lki3NFMh|ryPM2LKcXNCVkeHUh?=
U-87-MGNVX6SnBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vae2lEPTB;NEWuNVAzOiEQvF2=MUXTRW5ITVJ?
HAL-01M1zR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTR3LkGzO|kh|ryPM3jQPXNCVkeHUh?=
OVCAR-8M4rFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPHOJhKSzVyPUS1MlM2PjRizszNNF\GUFNUSU6JRWK=
KYSE-150MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVWwPJVjUUN3ME20O{4yODV{IN88US=>M3vKbHNCVkeHUh?=
OE33MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\xR4hmUUN3ME20O{4yPDJ7IN88US=>Mn[2V2FPT0WU
CAL-62NIL6NY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjqRVJlUUN3ME20O{41ODZ6IN88US=>MY\TRW5ITVJ?
TCCSUPNHHwSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXP0OHJ1UUN3ME20O{43OjZ2IN88US=>NYLBdmtSW0GQR1XS
H4NFvBbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnjTWM2OD12Nz62OlIyKM7:TR?=MWrTRW5ITVJ?
CP66-MELNVTmWmtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PKU2lEPTB;NEiuNFcxPCEQvF2=M333Z3NCVkeHUh?=
SNB75MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTR6LkG4O|Qh|ryPNH3jcWxUSU6JRWK=
Mo-TNELVdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2i1WGlEPTB;NEiuNlc6KM7:TR?=M3ewb3NCVkeHUh?=
BT-549M4nHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTR6LkO3Nlkh|ryPMVnTRW5ITVJ?
IGR-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjWTWM2OD12OD62OlQ2KM7:TR?=NYTCdWI1W0GQR1XS
NCI-H1299NHrTOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTR6LkeyOFgh|ryPMXHTRW5ITVJ?
ALL-POM2jLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\MOIhKSzVyPUS5MlkzPjhizszNMYfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. [2]
Features

Protocol(Only for Reference)

Cell Assay: [2]

Cell lines SW620, LoVo, V3-YAC and V3 cells
Concentrations 0.5 μM or 1 μM
Incubation Time 17 hours
Method The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min 137Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 105 per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

Animal Study: [2]

Animal Models Female rude mice bearing SW620 xenografts
Formulation Sterile 0.9% sodium chloride solution
Dosages 10 mg/kg
Administration Intraperitoneally administrated

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Leahy JJ, et al. Bioorg Med Chem Lett, 2004, 14(24), 6083-6087.

[2] Zhao Y, et al. Cancer Res, 2006 , 66(10), 5354-5362.

view more

Chemical Information

Download NU7441 (KU-57788) SDF
Molecular Weight (MW) 413.49
Formula

C25H19NO3S

CAS No. 503468-95-9
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 3 mg/mL (7.25 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4H-1-Benzopyran-4-one, 8-(4-dibenzothienyl)-2-(4-morpholinyl)-

Frequently Asked Questions

  • Question 1
    Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?

    Answer: Slight color variation due to different processing is normal and usually doesn't interfere with the function.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related DNA-PK Products

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • NU7026

    NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

  • KU-0060648

    KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • MK-2206 2HCl

    MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • CHIR-99021 (CT99021) HCl

    CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

Recently Viewed Items

Tags: buy NU7441 (KU-57788) | NU7441 (KU-57788) supplier | purchase NU7441 (KU-57788) | NU7441 (KU-57788) cost | NU7441 (KU-57788) manufacturer | order NU7441 (KU-57788) | NU7441 (KU-57788) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us